Lilly's retatrutide beats Ozempic on sugar and weight — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly said this morning that its investigational drug retatrutide was more effective than Novo Nordisk's Ozempic in a large diabetes study.
- Retatrutide lowered blood sugar more than Ozempic in the head-to-head comparison — one of two efficacy endpoints on which the investigational drug came out ahead.
- Ozempic also lost the weight comparison, with retatrutide producing greater weight reduction in the same study, leaving Novo Nordisk's drug behind on both measures Lilly reported.
- Retatrutide remains an investigational drug, so this is a clinical-stage result rather than a newly available treatment.
- STAT+ is keeping the full write-up exclusive to subscribers, so the excerpt discloses no effect sizes, doses or safety findings.
Why it matters: Lilly's investigational retatrutide beat Novo Nordisk's Ozempic on both blood sugar and weight in the same large diabetes study, leaving the incumbent trailing on the two endpoints Lilly measured. The excerpt discloses no percentages, doses or safety results, so the size of the gap and retatrutide's distance from approval remain unstated.
Ask SkimNews
